Welcome to a new episode of the

EUVC podcast

, where

and

of

and

from

gather to unpack the macro forces and micro signals shaping European tech and venture.

This week, the trio dive into:

• Why Europe’s fiscal firepower could be its unfair advantage
• The growing exodus of IPOs from the UK to the US
• Strategic defense investment—can the UK move the needle?
• How AI and capital markets are colliding
• And yes, we close on psychedelics and patient-first biotech breakthroughs

Here's what’s covered:

02:15 Europe’s Fiscal Advantage: Why Better Balance Sheets Matter for Innovation

07:00 The Return of Low Rates: What It Means for Startups

11:20 London vs. New York: The IPO Drain

17:00 Why Capital Leaves: Liquidity, Coverage & the Search for Growth

21:30 Rebuilding the UK Market: The Case for LP Allocation Reform

25:50 Beyond IPOs: The Full-Stack Capital Problem

30:40 AI and Lawsuits: Welcome to the New Frontier

33:10 Defense Tech Heats Up: Drones, AI & Strategic Capital

38:40 Can the UK Compete? Global Arms Races & National Reviews

42:30 Liquid Biopsies & Healthcare Breakthroughs

46:20 NHS Efficiency Crisis: More Money, Worse Outcomes

50:30 Psychedelics on the Edge: Awaiting the Data Drop